What You Need to Do to Prepare for a Successful Inspection?

 Course "How FDA Trains Its Investigators and Inspectors to Review Sub-Systems for State of Compliance: What You Need to Do to Prepare for a Successful Inspection" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Senior management takes responsibility for quality and GXP compliance. It is not something delegated to the quality unit or to the regulatory affairs group. Developing and implementing an effective inspection readiness plan will help ensure better results, as well as a less stressful Inspection. Planning strategically ahead will reduce document turn-around time, improve presentation skills from SMEs and increase inspector confidence in the quality system. Successfully completing a FDA inspection is critical to cGMP operations and commercial success. Implementing and maintaining robust quality systems is one element to accomplishing this goal. However, it is not the only element. Inspection preparation and management is another, equally important element to ensure a successful outcome. In fact, proper Inspection management techniques can help mitigate the risk of receiving an observation for compliance gaps. Quality and GXP compliance are an opportunity, not as an obligation, and are owned by everyone in the organization. For those interacting with FDA regarding submissions, as an example, every interaction with the FDA is a crucial moment for your development program, and meetings represent a culmination of compiled and scheduled work. Strategies, timelines, costs and complexity are all organized through this interaction - the stakes are high, and the outcomes are extremely important. It all comes down to strategic communication. Every facet of FDA meetings - from the information your company is providing, to scientific research and the tone and articulation of that information - must be conducted flawlessly. For example, for many medical device companies, a meeting with a US Food and Drug Administration (FDA) Advisory Committee is a high-profile, high-stress event. A successful meeting can assure regulators, patients and investors that a product is safe and effective, while an unsuccessful meeting can torpedo a product's chances at a timely approval. Why you should attend: • How a firm should prepare for an FDA inspection • Ways to train employees in view of the inspection • Field Management Directives • Sub-Systems for Pharmaceutical and Medical Devices • The emphasis on systems-based inspections...and the IOM, QSIT, CPGM and other crucial FDA reference documents • How to ensure that required documentation is in place • How to interact with the investigator-DO's and DON'T's • What companies should do when the inspection ends • Post inspection actions • Why inspections are conducted and by what statutory authority • The emphasis on systems-based inspections...and the IOM and other crucial FDA reference documents • Define and execute proven GxP Compliance Strategies • Proven Operational Readiness and State of Readiness tactics • Determine optimal pathway during inspections and post-inspection correspondence and meetings • Identify the visible signs of GXP compliance that are present as a daily reminder of the importance of GXP compliance with "risk-based" awareness demonstrated by companies • Improve credibility and trust with FDA and other regulators • Important training areas in GxP compliance and topical issues • Gain a better understanding of how to interact and communicate effectively with FDA • Identify the ground rules and do's and don'ts with FDA inspections • Learn what FDA can request and not request during an inspection • Understanding the interview process and why pre-inspection planning is critical for your company • Navigate the inspection process from preparation, execution to close-out and debrief/exist interview • FDA authority and process including 483s, Warning Letters, recalls, and other potential actions • The FDA inspection process and approach • The use of a mock audit and outside certifying audit • Required documentation, format, and archive • How to respond to inspection and audit results • In a group setting, review and discuss pain points, challenges and workable regulatory and compliance solutions for any FDA inspection • Prepare for lively discussions and a Mock Inspection as part of a classroom exercise • Communicate effectively with FDA and reference FDA guidance and other critical resources Who will benefit: This seminar will provide an overview and in-depth snapshot of the entire process for preparing for and managing and FDA inspection and external regulatory inspections and for those companies who must establish proven and sustainable GXP Compliance Strategies and risk mitigation strategies when responding to a crisis. Employees who will benefit include all levels of management and departmental representatives from key functional areas and those who desire a better understanding or a "refresh" overview of the FDA inspection process from preparing for the inspections, during the inspections and post-inspection responsibilities and follow up activities with FDA, including: • Executive Management • Regulatory Affairs Management • Regulatory Affairs Specialist • Auditors • QC/QC Management • Compliance Officer • Compliance Specialist • Clinical Affairs • Quality Assurance Management • Marketing & Sales • Laboratory Operations • Distributors/Authorized Representatives • Legal Counsel • Engineering/Technical Services • Operations/Manufacturing • Consultants • Individuals who come in contact with regulatory inspectors • Auditors • Compliance/Regulatory affairs professionals • QA/QC professionals • Manufacturing managers, supervisors & personnel • Project Managers • Regulatory Affairs Management • Regulatory Affairs Specialist • Compliance Officer • Compliance Specialist • Clinical Affairs • Distributors • Legal Counsel Agenda: Day 1 Schedule ________________________________________ Lecture 1: Introductions and Background ________________________________________ Lecture 2: FDA's Inspectional Authority and History ________________________________________ Lecture 3: FDA Inspection Program Overview ________________________________________ Lecture 4: Key factors for a successful FDA inspection ________________________________________ Lecture 5: Quality System Readiness ________________________________________ Lecture 6: Organization Readiness ________________________________________ Lecture 7: Manage Inspection Outcomes ________________________________________ Lecture 8: Information and Documentation ________________________________________ Lecture 9: How a firm should prepare for an FDA inspection? ________________________________________ Lecture 10: Ways to train employees in view of the inspection ________________________________________ Lecture 11: How to ensure that required documentation is in place ________________________________________ Lecture 12: How to interact with the investigator-DO's and DON'T's ________________________________________ Lecture 13: What companies should do when the inspection ends ________________________________________ Lecture 14: How to reply to 483's and warning letters ________________________________________ Lecture 15: Legal implications of non-compliance ________________________________________ Lecture 16: Why inspections are conducted and by what statutory authority ________________________________________ Lecture 17: The emphasis on systems-based inspections...and the IOM and other crucial FDA reference documents such as QSIT ________________________________________ Lecture 18: What is subject to FDA purview and what's off-limits ________________________________________ Lecture 19: Understand and apply the do's and don'ts and comprehend that preparation is the key to success ________________________________________ Lecture 20: What are the prohibited "Acts" and the enforcement categories that you need to deal with? ________________________________________ Lecture 21: What you need to know and do to prepare for, during and even after the inspection...and why your inspection response team is key ________________________________________ Lecture 22: The company's Inspection Plan (SOP) can make or break the inspection depending on how to use it and training your personnel ________________________________________ Lecture 23: How to respond to findings and facilitating the documentation and remediation process...and reaching final closure ________________________________________ Lecture 24: Define clear responsibilities, roles and goals for personnel involved in FDA inspections and SOP development ________________________________________ Lecture 25: Exit Interview ________________________________________ Lecture 26: FDA interviewing employees and personnel ________________________________________ Lecture 27: Management Controls, Production and Process Controls, Design Controls, CAPA, and sub-systems Day 2 Schedule ________________________________________ Lecture 1: Quality System, Facilities and Equipment System, Materials System, Production System, Laboratory Controls and Operations, Packaging and Labeling System ________________________________________ Lecture 2: Maintain, or return to, regulatory compliance and minimize downtime ________________________________________ Lecture 3: Establish a risk management plan in place to proactively manage compliance, including a crisis-management plan ________________________________________ Lecture 4: Set post-inspection deadlines and working closely with FDA's regulatory partners ________________________________________ Lecture 5: Compliance remediation is the process of recognizing problems, creating a plan to correct and prevent them from occurring in the future, and executing to that plan to helps with your GxP Compliance Strategy. ________________________________________ Lecture 6: Guidance outlining clear recommendations for sponsors and for FDA staff and managers as well for Pre-Submission meetings as expected timeframes for scheduling meetings ________________________________________ Lecture 7: Mechanics of requesting any FDA meeting and what you need to know to be successful with communication style, approach and tactics ________________________________________ Lecture 8: Prioritize follow-up on warning letters and other enforcement actions ________________________________________ Lecture 9: Develop and implement a formal warning letter "close-out" process ________________________________________ Lecture 10: Untitled Letter and the Warning Letters ________________________________________ Lecture 11: Recent Trends and Enforcement Actions ________________________________________ Lecture 12: Mock Inspections and Mock Audits and why role playing is important ________________________________________ Recap of Day 1 and Day 2 ________________________________________ Exercise on Day 2 • Interactive Discussions • Review Regulatory and Compliance Documentation • Recent Enforcement Actions and Emerging FDA Trends • Classroom Project: Prepare for and Host an FDA Mock Inspection and Prepare Effective Company Response to FDA 483 and/or Warning Letter Speaker David R. Dills Global Regulatory Affairs & Compliance Consultant and President, NovaQual David R. Dills, Global Regulatory Affairs & Compliance Consultant, Interim President, currently provides global regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III medical device, including combination products, In Vitro Diagnostics, nutraceuticals/supplements, cosmetics and biopharmaceutical manufacturers in multiple medical specialties and therapeutic areas on the global landscape, and has an accomplished record with more than 26 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by medical device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA's, warning letters,483 observations, and customer generated compliance events, and prepares for and conducts QS and regulatoryaudits. He is currently acting and interim President at NovaQual LLC. Location: Washington, DC Date: June 6th & 7th, 2018 and Time: 9:00 AM to 6:00 PM Venue: Courtyard Arlington Crystal City/Reagan National Airport 2899 Jefferson Davis Highway Arlington, VA 22202 USA Price: Price: $1,295.00 (Seminar Fee for One Delegate) Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)* Register for 10 attendees Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)* Register now and save $200. (Early Bird) Until May 10, Early Bird Price: $1,295.00 From May 11 to June 04, Regular Price: $1,495.00 Sponsorship Program benefits for “Biostatistics for Non-Statistician” seminar For More Information- https://www.globalcompliancepanel.com/control/sponsorship Contact us today! NetZealous LLC DBA GlobalCompliancePanel john.robinson@globalcompliancepanel.com Toll free: +1-800-447-9407 Phone: +1-510-584-9661 Website: http://www.globalcompliancepanel.com Registration Link - https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901747SEMINAR?SEO Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanelindia/ Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/ Follow us on Twitter: https://twitter.com/GCPanel